Alnylam chalks up another win with trial of a liver-disease drug – STAT
The drug, based on RNA interference technology, silences a gene critical to the development of damaging and painful kidney stones.
Related Articles
GLP-1 reduced migraine frequency by nearly half, in a pilot study
Researchers say GLP-1 agonists significantly reduced migraine frequency in participants who were obese.
Senate Republicans debate Medicaid options as hospitals move to shape legislation
The Senate returns next week with critical choices on Medicaid policies that could cost hospitals billions of dollars and lead to millions losing coverage.
Nominate a 2024 STAT Wunderkind
Nominate a 2024 STAT Wunderkind STAT Wunderkinds is a chance to celebrate early-career researchers who are not yet independent scientists or program
Does the FDA commissioner’s new voucher program open a Pandora’s box?
The FDA is setting up a pilot program to review some drugs within one to two months. How fast is too fast?
Disagreements over Duchenne therapy, management style may have led to ouster of key FDA official
The ouster of the FDA’s chief regulator of cell and gene therapies came immediately after a disagreement with her boss over a drug review, STAT…
Why MAHA wants whole milk back on the table
In the nutrition world, the question of how whole milk compares with lower-fat options is the subject of debate. In MAHA world, it’s time to…
Cogent Biosciences-Blueprint Medicines tiff turns spicy on eve of immune drug study readout
A rivalry between two drugmakers, Cogent Biosciences and Blueprint Medicines, has turned ugly.
Supreme Court ruling on gender-affirming care delivers major setback for transgender rights
Tennessee’s ban on gender-affirming care for minors can stand after the Supreme Court ruled that it does not constitute sex-based discrimination, in a 6-3 decision.
Gilead’s CEO on the approval of a powerful new drug to prevent HIV
Gilead’s CEO says he’s committed to making sure people around the world can get his firm’s new HIV prevention shot Yeztugo.